Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth

Development of Gene Therapeutics for Head and Neck Cancer in China: From Bench to Bedside

(2018) Wei Guo et al.   HUMAN GENE THERAPY

Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector

(2017) Rodrigo Esaki Tamura et al.   HUMAN GENE THERAPY

Autoregulated expression of p53 from an adenoviral vector confers superior tumor inhibition in a model of prostate carcinoma gene therapy

(2016) Rodrigo Esaki Tamura et al.   CANCER BIOLOGY & THERAPY

Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

(2015) Masahiro Nozawa et al.   International Journal of Clinical Oncology

Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme

(2014) Axel Heidenreich et al.   EUROPEAN JOURNAL OF CANCER

Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters

(2014) Jayne Loughery et al.   NUCLEIC ACIDS RESEARCH

Combined p19Arf and interferon-beta gene transfer enhances cell death of B16 melanoma in vitro and in vivo

(2013) C A Merkel et al.   CANCER GENE THERAPY

AAVPG: A vigilant vector where transgene expression is induced by p53

(2013) Marcio C. Bajgelman et al.   VIROLOGY

Functional p53 determines docetaxel sensitivity in prostate cancer cells

(2012) Chengfei Liu et al.   PROSTATE

Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element

(2012) Jui-Chuan Chuang et al.   TOXICOLOGY IN VITRO

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling

(2011) Lu Gan et al.   PROSTATE

Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6

(2010) Christian A Merkel et al.   BMC CANCER

Efficacy of Oncolytic Mutants Targeting pRb and p53 Pathways Is Synergistically Enhanced When Combined with Cytotoxic Drugs in Prostate Cancer Cells and Tumor Xenografts

(2010) Suresh Radhakrishnan et al.   HUMAN GENE THERAPY

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Development of an adenoviral vector with robust expression driven by p53

(2008) Marcio C. Bajgelman et al.   VIROLOGY